Clinical trial
Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT)…
NCT00499837 · Kamada, Ltd., Industry · Completed
Key facts
| NCT number | NCT00499837 |
|---|---|
| Title | Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients |
| Official title | Double-Blind, Randomized, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients |
| Lead sponsor | Kamada, Ltd., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | Aerosolized, human, plasma-derived Alpha-1 Antitrypsin |
| Enrollment | 21 |
| Start date | Sep 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jul 12, 2007 |
| Last update posted | Jun 9, 2016 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: